Table 4.
Summary of outcomes for postoperative therapy in patients with esophageal cancer after neoadjuvant therapy and surgery
| Reference (first author) | Year | Histology | Neoadjuvant treatment | Adjuvant treatment | OS | p |
|---|---|---|---|---|---|---|
| Drake et al. [24] | 2019 | AC | CT | CT/observation |
Median 31.2 M/24.0 M |
0.031 |
| Semenkovich et al. [25] | 2019 | AC/SCC | RT | CT or CRT/observation |
Median 2.6 Y/2.3 Y |
0.02 |
| Yan et al. [26] | 2019 | SCC | CT | CT/observation |
5-Y OS 62.4%/68.6% |
0.359 |
| Our studya | 2020 | SCC | CT | CT/observation |
Median Not reached/20.1 M |
0.040 |
AC adenocarcinoma, SCC squamous cell carcinoma, CT chemotherapy, RT radiotherapy, CRT chemoradiotherapy, M month, Y year
aThoracic esophageal cancer patients with two or more positive lymph nodes